MX2010010457A - Vectores recombinantes de rinovirus. - Google Patents

Vectores recombinantes de rinovirus.

Info

Publication number
MX2010010457A
MX2010010457A MX2010010457A MX2010010457A MX2010010457A MX 2010010457 A MX2010010457 A MX 2010010457A MX 2010010457 A MX2010010457 A MX 2010010457A MX 2010010457 A MX2010010457 A MX 2010010457A MX 2010010457 A MX2010010457 A MX 2010010457A
Authority
MX
Mexico
Prior art keywords
rhinovirus vectors
vectors
recombinant rhinovirus
recombinant
immunogens
Prior art date
Application number
MX2010010457A
Other languages
English (en)
Inventor
Kirill Kalnin
Yanhua Yan
Maryann Giel-Moloney
Harold Kleant-Hous
Original Assignee
Sanofi Pasteur Biologics Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Co filed Critical Sanofi Pasteur Biologics Co
Publication of MX2010010457A publication Critical patent/MX2010010457A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32741—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención proporciona vectores de rinovirus, los cuales pueden usarse en la entrega de inmunógenos, tales como inmunógenos de virus de la influenza, y composiciones y métodos correspondientes.
MX2010010457A 2008-03-27 2009-03-27 Vectores recombinantes de rinovirus. MX2010010457A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7203608P 2008-03-27 2008-03-27
PCT/US2009/001941 WO2009120380A2 (en) 2008-03-27 2009-03-27 Recombinant rhinovirus vectors

Publications (1)

Publication Number Publication Date
MX2010010457A true MX2010010457A (es) 2010-11-05

Family

ID=41114548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010457A MX2010010457A (es) 2008-03-27 2009-03-27 Vectores recombinantes de rinovirus.

Country Status (11)

Country Link
US (1) US20110091501A1 (es)
EP (1) EP2257308A4 (es)
JP (1) JP2011517408A (es)
KR (1) KR20110005826A (es)
CN (1) CN102089003A (es)
AU (1) AU2009229165A1 (es)
BR (1) BRPI0909119A2 (es)
CA (1) CA2718731A1 (es)
IL (1) IL208321A0 (es)
MX (1) MX2010010457A (es)
WO (1) WO2009120380A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2664791A1 (en) * 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co. Recombinant rhinovirus vectors
US9241986B2 (en) * 2010-01-04 2016-01-26 Kj Biosciences Llc DPS fusion proteins for use in vaccines and diagnostics
US9566307B2 (en) * 2012-04-19 2017-02-14 Kyushu University, National University Corporation Pharmaceutical composition
EP2765137A1 (en) * 2013-02-07 2014-08-13 Sanofi Pasteur Induction of cross-reactive cellular response against rhinovirus antigens
WO2016042059A1 (en) * 2014-09-18 2016-03-24 Glaxosmithkline Biologicals S.A. Vaccine
PT3095866T (pt) 2015-05-20 2019-06-18 Secarna Pharmaceuticals Gmbh & Co Kg Agente de profilaxia e terapia de infeções virais
EP3103474A1 (en) * 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
WO2016205389A1 (en) * 2015-06-15 2016-12-22 Emory University Multivalent enterovirus vaccine compositions and uses related thereto
US10428116B2 (en) * 2016-04-22 2019-10-01 Wisconsin Alumni Research Foundation Rhinovirus C immunogenic peptides
CN109694401A (zh) * 2017-10-20 2019-04-30 金协国际实业有限公司 败血性巴氏杆菌毒素重组蛋白、其类病毒颗粒及其应用
WO2023005805A1 (zh) * 2021-07-26 2023-02-02 北京万泰生物药业股份有限公司 人鼻病毒的通用亲和表位多肽、抗体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714374A (en) * 1990-09-12 1998-02-03 Rutgers University Chimeric rhinoviruses
US5541100A (en) * 1990-09-12 1996-07-30 Rutgers University Chimeric rhinoviruses
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
EP1256803A1 (en) * 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
JP2005501532A (ja) * 2001-06-01 2005-01-20 アカンビス インコーポレーティッド キメラフラビウイルスベクター
US20060088549A1 (en) * 2004-07-08 2006-04-27 Arnold Gail F Chimeric virus vaccine
US20100086485A1 (en) * 2006-01-17 2010-04-08 Heiko Apfel Influenza vaccine
EP3011969A1 (en) * 2006-03-07 2016-04-27 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
ZA200901993B (en) * 2006-09-29 2010-07-28 Sanofi Pasteur Biologics Co Novel neutralizing immunogen (NIMIV) of rhinovirus and its use for vaccine applicants
CA2664791A1 (en) * 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co. Recombinant rhinovirus vectors
CA2676689C (en) * 2007-01-31 2014-12-16 Sanofi Pasteur Biologics Co. Recombinant bicistronic flavivirus vectors
US20110110973A1 (en) * 2008-02-09 2011-05-12 Sanofi Pasteur Biologics Co. Influenza B Vaccines
UA103316C2 (uk) * 2008-03-14 2013-10-10 Санофі Пастер Біолоджікс Ко. Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин

Also Published As

Publication number Publication date
WO2009120380A3 (en) 2009-12-30
EP2257308A2 (en) 2010-12-08
AU2009229165A1 (en) 2009-10-01
IL208321A0 (en) 2010-12-30
CN102089003A (zh) 2011-06-08
US20110091501A1 (en) 2011-04-21
JP2011517408A (ja) 2011-06-09
EP2257308A4 (en) 2012-06-27
CA2718731A1 (en) 2009-10-01
BRPI0909119A2 (pt) 2017-06-13
KR20110005826A (ko) 2011-01-19
WO2009120380A2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
MX2010010457A (es) Vectores recombinantes de rinovirus.
UA103316C2 (uk) Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
EA201100268A1 (ru) Вакцина
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
GB0917002D0 (en) Improved shigella blebs
MX2010004374A (es) Armazones proteinicos.
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
JO2860B1 (en) Phenylendazolyl compounds
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
SG195194A1 (en) Nanogels
PH12012502452A1 (en) Vectors and sequences for the treatment of diseases
MY181898A (en) Heterocyclic compounds and uses thereof
MY161495A (en) Virus like particle compositions and methods of use
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
MX2011008179A (es) Peptidos para vacuna.
WO2011098778A3 (en) Peptides for vaccines against birch allergy
WO2009152167A3 (en) Delivery of therapeutics
MX2009003300A (es) Vectores de rhinovirus recombinantes.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal